This meta-analysis suggests that 4 mg of saroglitazar reduces triglyceride, LDL-C, and total cholesterol levels in patients with dyslipidemia; however, there were no significant changes in apolipoprotein B levels. This evidence concerns the gene APOB and metabolic syndrome.